Cara Therapeutics Inc (CARA)

[seppi08162]

If you're referring to the OA Pain trials, they were expanded due to inefficacy of low doses (below 5mg). In order to satisfy endpoints, doses will be increased (10mg, +) to show CR845's efficacy. There will be very little news over the next several months due to timing of upcoming catalysts. I suspect the earnings report will be our next and final catalyst until january, and given the need to expand the OA trials, i suspect the earnings call will disappoint (potential need for funding sooner than the initial 2019 timeline given last call) and we should expect to see share price fall closer to the $10 range, possibly lower. If im wrong that would be nice- short term; however, if you're a believer in this team you might appreciate the opportunity to acquire cheap shares- personally, I am. Cara long.
Good luck to all.